Shindo Yuji, Matsumoto Satohiro, Miyatani Hiroyuki, Yoshida Yukio, Mashima Hirosato
Yuji Shindo, Satohiro Matsumoto, Hiroyuki Miyatani, Yukio Yoshida, Hirosato Mashima, Department of Gastroenterology, Jichi Medical University, Saitama Medical Center, Saitama 330-8503, Japan.
World J Gastrointest Endosc. 2016 Apr 10;8(7):349-56. doi: 10.4253/wjge.v8.i7.349.
To evaluate the risk factors for postoperative bleeding after gastric endoscopic submucosal dissection (ESD) based on the latest guidelines.
A total of 262 gastric neoplasms were treated by ESD at our center during a 2-year period from October 2012. We analyzed the data of these cases retrospectively to identify the risk factors for post-ESD bleeding.
Of the 48 (18.3%) cases on antithrombotic treatment, 10 were still receiving antiplatelet drugs perioperatively, 13 were on heparin replacement after oral anticoagulant withdrawal, and the antithrombotic therapy was discontinued perioperatively in 25 cases. Postoperative bleeding occurred in 23 cases (8.8%). The postoperative bleeding rate in the heparin replacement group was 61.5%, significantly higher than that in the non-antithrombotic therapy group (6.1%). Univariate analysis identified history of antithrombotic drug use, heparin replacement, hemodialysis, cardiovascular disease, diabetes mellitus, elevated prothrombin time-international normalized ratio, and low hemoglobin level on admission as risk factors for post ESD bleeding. Multivariate analysis identified only heparin replacement (OR = 13.7, 95%CI: 1.2-151.3, P = 0.0329) as a significant risk factor for post-ESD bleeding.
Continued administration of antiplatelet agents, based on the guidelines, was not a risk factor for postoperative bleeding after gastric ESD; however, heparin replacement, which is recommended after withdrawal of oral anticoagulants, was identified as a significant risk factor.
基于最新指南评估胃内镜黏膜下剥离术(ESD)术后出血的危险因素。
2012年10月起的2年期间,我院中心共对262例胃肿瘤患者实施了ESD治疗。我们对这些病例的数据进行回顾性分析,以确定ESD术后出血的危险因素。
48例(18.3%)接受抗血栓治疗的患者中,10例围手术期仍在服用抗血小板药物,13例在停用口服抗凝剂后接受肝素替代治疗,25例围手术期停用抗血栓治疗。23例(8.8%)发生术后出血。肝素替代治疗组的术后出血率为61.5%,显著高于非抗血栓治疗组(6.1%)。单因素分析确定抗血栓药物使用史、肝素替代治疗、血液透析、心血管疾病、糖尿病、凝血酶原时间-国际标准化比值升高及入院时血红蛋白水平低为ESD术后出血的危险因素。多因素分析仅确定肝素替代治疗(比值比=13.7,95%置信区间:1.2-151.3,P=0.0329)为ESD术后出血的显著危险因素。
根据指南持续使用抗血小板药物并非胃ESD术后出血的危险因素;然而,口服抗凝剂停用后推荐的肝素替代治疗被确定为显著危险因素。